Status:

RECRUITING

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

Lead Sponsor:

University of California, San Francisco

Conditions:

COVID

Eligibility:

All Genders

18-100 years

Brief Summary

LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a sp...

Detailed Description

LIINC is an observational, prospective study of individuals previously infected with SARS-CoV-2 who have recovered from acute illness. The overall objective of the study is to investigate the clinical...

Eligibility Criteria

Inclusion

  • Willing and able to provide written informed consent, and
  • Age \>/= 18 years, and
  • A history of SARS-CoV-2 infection, as evidenced by:
  • Available laboratory documentation of SARS-CoV-2 RNA positivity on a nucleic acid amplification test or by serologic testing when this becomes available, or
  • Reference by the participant to a laboratory test performed on respiratory tract secretions or blood, fingerstick, or saliva test that was reported to the participant to be positive for SARS-CoV-2 or COVID-19 infection,
  • And a period of 21 days or more has elapsed since the first positive test or symptoms preceding the first positive test, whichever is earlier.

Exclusion

  • Self-reported or documented chronic anemia with hemoglobin \< 9 g/dL. Anemia during a preceding acute illness will not be exclusionary.
  • Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent.
  • Active drug or alcohol use or dependence that, in the opinion of the Principal Investigator, would interfere with adherence to study requirements or to give informed consent.

Key Trial Info

Start Date :

April 21 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2030

Estimated Enrollment :

800 Patients enrolled

Trial Details

Trial ID

NCT04362150

Start Date

April 21 2020

End Date

December 31 2030

Last Update

June 12 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zuckerberg San Francisco General Hospital (ZSFG)

San Francisco, California, United States, 94110